MiMedx Group FY2025 EPS Estimate Lifted by Northland Capmk

Key Points

• Northland Capital Markets has raised its FY2025 earnings per share estimate for MiMedx Group from $0.28 to $0.32, indicating a positive outlook for the company.
• The shares of MiMedx Group are rated as "overweight" by Cantor Fitzgerald, which increased their price target from $11.00 to $12.00.
• MiMedx Group reported a quarterly revenue of $98.61 million, exceeding analysts' expectations of $90.79 million, with a notable earnings per share performance of $0.10.

MiMedx Group, Inc (NASDAQ:MDXG - Free Report) - Equities researchers at Northland Capmk boosted their FY2025 EPS estimates for shares of MiMedx Group in a research note issued to investors on Thursday, July 31st. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings of $0.32 per share for the year, up from their prior forecast of $0.28. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group's FY2026 earnings at $0.34 EPS.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.04. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. The firm had revenue of $98.61 million for the quarter, compared to the consensus estimate of $90.79 million.

Other equities research analysts also recently issued reports about the company. Cantor Fitzgerald lifted their price objective on MiMedx Group from $11.00 to $12.00 and gave the stock an "overweight" rating in a report on Thursday, July 31st. Wall Street Zen upgraded MiMedx Group from a "hold" rating to a "strong-buy" rating in a report on Saturday.

MiMedx Group Trading Down 1.0%

MDXG stock traded down $0.08 on Friday, reaching $7.08. The company's stock had a trading volume of 225,766 shares, compared to its average volume of 692,807. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.90 and a current ratio of 4.39. The firm has a market cap of $1.05 billion, a PE ratio of 33.69 and a beta of 1.79. The business has a fifty day simple moving average of $6.45 and a two-hundred day simple moving average of $7.23. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $10.14.

Hedge Funds Weigh In On MiMedx Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. First Light Asset Management LLC bought a new stake in MiMedx Group during the fourth quarter valued at about $32,168,000. Millennium Management LLC boosted its position in MiMedx Group by 93.9% during the first quarter. Millennium Management LLC now owns 1,230,984 shares of the company's stock valued at $9,355,000 after purchasing an additional 596,016 shares in the last quarter. Meros Investment Management LP boosted its position in MiMedx Group by 107.7% during the first quarter. Meros Investment Management LP now owns 820,605 shares of the company's stock valued at $6,237,000 after purchasing an additional 425,531 shares in the last quarter. Norges Bank bought a new stake in MiMedx Group during the fourth quarter valued at about $4,020,000. Finally, JPMorgan Chase & Co. raised its stake in MiMedx Group by 133.1% in the fourth quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock valued at $6,668,000 after buying an additional 395,739 shares during the last quarter. Institutional investors own 79.15% of the company's stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.